Summer Sale: Save 51% on Pro and invest smartly

[edd_has_expired_licenses]

Summer Sale: Save 51% on Pro and invest smartly

[/edd_has_expired_licenses]

Johnson & Johnson’s Revenue Breakdown (2016-2021)

Exclusive Data

You need the Pro Plan for unlimited access.

Pro Plan

$39 per month*

51% discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

Download

About

This statistic covers Johnson & Johnson’s Revenue Breakdown, split across Consumers, Medical Devices, and Pharmaceutical from 2016 onwards.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information
Subscribe to Pro or Enterprise plans to unlock this feature.
Contact the Analyst
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on reddit
Share on facebook
Share on twitter
Share on linkedin
Share on email

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPIs & Segment Financials on US stocks

This statistic covers Johnson & Johnson’s Revenue Breakdown, split across Consumers, Medical Devices, and Pharmaceutical from 2016 onwards.

Johnson & Johnson generates revenue from the following segments:

  • Consumer
  • Medical Devices
  • Pharmaceutical

Johnson & Johnson’s Revenue Breakdown

Segment Q4 2019 Q4 2020 YoY Growth Revenue Share Q4 2020
Consumer $3.57 $3.62 1.40% 16.84%
Medical Devices $6.63 $5.93 -10.55% 27.58%
Pharmaceutical $10.76 $11.95 11.05% 55.58%
Total Revenue $20.96 $21.50 2.57% 100.00%

(all figures in billions, except percentages)

Johnson & Johnson’s total revenue rose from $20.96 billion in Q4 2019 to $21.50 billion in Q4 2020, marking an increase of 2.57% on a year-on-year basis. During this period, the revenue growth was driven by higher sales of medicines like Stelara, Darzalex, Imbruvica, Opsumit, and Tremfya.

Consumer

Johnson & Johnson’s Consumer segment offers a variety of products for oral care, baby care, skincare, and many other personal healthcare products. The company’s major brands include Clean & Clear, Neutrogena, Aveeno, Benadryl, Nicorette, Listerine, Stayfree, Carefree, Band-Aid, Neosporin, and many others. These products are used for the treatment of allergy, cough and cold, smoking cessation, and pain relief. Johnson & Johnson sells these products in different parts of the world through retail outlets, distributors, and e-commerce websites.

Johnson & Johnson’s revenue from the Consumer segment increased from $3.57 billion in Q4 2019 to $3.62 billion in Q4 2020, a growth of 1.40% on a year-on-year basis. In Q4 2020, the Consumer segment contributed 16.84% to the company’s total revenue. 

Medical Devices

Johnson & Johnson’s Medical Devices segment includes various types of devices used in Surgery, Interventional Solutions, Orthopaedics, and Vision Fields. 

  • Surgery: Johnson & Johnson provides solutions for ear, nose, and throat procedures, and other advance and general surgeries.
  • Interventional Solutions: The company provides medical devices for the treatment of cardiovascular diseases, hemorrhagic and ischemic stroke.
  • Orthopedics: Johnson & Johnson’s Orthopedic portfolio consists of orthopedic products for hips, trauma, knees, and spine. The company’s major brand in the orthopedic segment is Depuy Synthes.
  • Vision Fields: Johnson & Johnson Vision Fields product portfolio includes ophthalmic products for laser refractive surgery and cataract. The company’s major brand in this segment is Acuvue.

The company distributes these products to retailers and hospitals and is used by doctors, nurses, ophthalmologists, and physicians.

Johnson & Johnson’s revenue from the Medical Devices segment declined from $6.63 billion in Q4 2019 to $5.93 billion in Q4 2020, marking a decline of 10.55% on a year-on-year basis. During this period, the Medical Devices segment contributed 27.58% to Johnson & Johnson’s total revenue.

Pharmaceutical

Johnson & Johnson’s Pharmaceutical segment focuses on Immunology, Pulmonary Hypertension, Neuroscience, Infectious Diseases, Cardiovascular and Metabolism, and Oncology. The company’s major brands in the Pharmaceutical segment includes:

  • Stelara: used in the treatment of severe plaque psoriasis in children and adults.
  • Remicade: used in the treatment of immune-mediated inflammatory diseases.
  • Risperdal Consta: used in the treatment of schizophrenia and bipolar disorder in adults.
  • Opsumit: used in the treatment of pulmonary arterial hypertension.
  • Invokamet SR: used in the treatment of type 2 diabetes in adults.

Johnson & Johnson’s revenue from the Pharmaceutical segment rose from $10.76 billion in Q4 2019 to $11.95 billion in Q4 2020, a growth of 11.05% on a year-on-year basis. In Q4 2020, the Pharmaceutical segment contributed 55.58% to Johnson & Johnson’s total revenue. 

Company Overview

Johnson & Johnson is an American multinational healthcare company. The company was founded by James Johnson, Edward Johnson, and Robert Johnson in 1886. Johnson & Johnson’s main office is located in New Brunswick, New Jersey, United States. Alex Gorsky is the current Chairman and CEO of the company. Johnson & Johnson employs more than 130,000 people in different parts of the world. The company’s products are available in most parts of the world. Johnson & Johnson’s manufacturing facilities are located in United States, Europe, Africa, Asia, and the Pacific.

Johnson & Johnson faces tough competition from Novartis, Merck, Roche, Boston Scientific, Abbott, Glaxo Smith Kline, Pfizer, and Medtronic. Over the years, Johnson & Johnson has acquired companies like Momenta Pharmaceuticals, Mitek Products, Janssen, 3-Dimensional Pharmaceuticals, Auris Health, Verb Surgical, Taris Biomedical, and many more. These acquisitions have helped the company in increasing its product portfolio and fight competition in the markets. Johnson & Johnson is listed on the NYSE and is traded under the stock code “JNJ”.

Did you like Johnson & Johnson’s Revenue Breakdown statistic?

Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.

You can also get started for free.

Read more

Access Segment financials and KPI data on US stocks

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

Get to know us

  • Access basic data
  • No credit card required
$0
per month
Start for Free

51% discount until October 31

Pro

For serious investing

  • Granular KPI data Access segment financials, non-GAAP metrics and KPI data from presentations and filings. Examples include financials by segment / region / product category, AT&T's broadband subscriber trends, Tesla's deliveries by model and lots more.
  • Stock research tools Features include : Stock screener, Stock comparison, sector financials, stock warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Industry data & tools Access premium operating data on 40+ industries. Examples include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$39
$19
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our dashboards and dossiers.
  • Custom built features Get tailored dashboards built specially for you , based on your set of requirements, to simplify your research workflow.
$99
per month, onwards*
Contact Us

* Billed annually, local taxes extra. 

Basic

Get to know us

  • Access basic data
  • No credit card required
$0
per month
Start for Free

51% discount on Annual plan

Pro

For serious investing

  • Granular KPI data Access segment financials, non-GAAP metrics and KPI data from presentations and filings. Examples include financials by segment / region / product category, AT&T's broadband subscriber trends, Tesla's deliveries by model and lots more.
  • Stock research tools Features include : Stock screener, Stock comparison, sector financials, stock warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Industry data & tools Access premium operating data on 40+ industries. Examples include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$39
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our features.
  • Custom built features Get tailored dashboards built specially for you , based on your set of requirements, to simplify your research workflow.
$99
per month, onwards*
Contact Us

* Local taxes extra. 

BQ Star 51% off

Get Pro for 51% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $39 $19 / month

.